Target detail
ACR
acrosin
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: acrosin
Aliases: ACR, acrosin
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000100312
Index freshness: last_synced_at 2026-05-15T19:00:45.311+00:00 · updated 2026-05-15T19:00:45.816599+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ACR. Empty groups mean no matching rows — not a claim about biology or clinical use.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
Rows from disease_target_evidence for this symbol.
No matching live evidence found
Ingest Open Targets disease–target rows for this symbol to populate this section.
Drug records tied via drug_targets — mechanistic linkage only.
No linked drug rows
When drug_targets and drugs rows exist for this symbol, they are listed here.
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
NCT03660761 — Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT07411690 — Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT00293423 — GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT07552233 — NK Cell Therapy for Malignant Solid Brain Tumors
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT01985256 — Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03176160 — LITT Palliative Treatment for Patients With Malignant Gliomas
Status: WITHDRAWN · clinicaltrials.gov
Open trials hubNCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT06160596 — Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT02431572 — A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT07493447 — Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Status: NOT_YET_RECRUITING · clinicaltrials.gov
Open trials hubNCT05708352 — A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT05241392 — Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubRepurposing signal rows for drugs linked to this target via drug_targets.
No research signals for linked drugs
Run the deterministic signal builder after drug_targets and source rows are present.
Structured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
This symbol is listed in the canti target index — drug_targets and disease_target_evidence may still be empty until connector jobs populate those tables.
- clinicaltrials.gov: 14
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
No matching live evidence found
When repurposing_signal rows reference this marker via linked drugs, summaries appear here.